Shattuck Labs Inc (STTK) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Shattuck Labs Inc   (NASDAQ: STTK)


Shattuck Labs Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Shattuck Labs Inc's ROI in the second quarter of 2026?
Shattuck Labs Inc recorded a cumulative net loss of $-53 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -42.93%.

Within the Healthcare sector 432 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3642 to 3805.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 57.82 % -7.95 % -27.91 % -37.7 % -38.94 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 213 98 84 95 59
Return On Investment (TTM) -42.93 % -59.4 % -63.42 % -71.75 % -79.29 %
STTK's Overall Ranking # 3805 # 3642 # 2695 # 2503 # 3229
Seq. Investment Change TTM 45.82 % 9.1 % 0.6 % -1.39 % -14.95 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -53 -50 -49 -55 -62

STTK Company Profile >> Back to STTK Roi Comparisons >> See Annual STTK Return On Investment



Return On Investment STTK's Ranking
Within: No.
Industry # 173
Sector # 433
Overall # 3805

Return On Investment Statistics
High Average Low
-15.09 %
-49.59 %
-79.29 %
(Dec 31 2021)   (Jun 30 2025)



  News about Shattuck Labs Inc Return on Investment ROI

Navigating the Frontier of Innovation Shattuck Labs’ Pioneering DR3 Antagonist and Shifting Pathways in AML and MDS...

October 1, 2024

Innovative Therapies in the Spotlight: Shattuck Labs Pioneering DR3 Antagonist and New Insights into SL-172154 The biotechnology sector is on a relentless quest to develop innovative drug therapies for complex and life-threatening diseases. Shattuck Labs, a frontrunner in this arena, is driving forward with its groundbreaking pipeline. Recently, the company has made significant announcements that underscore its commitment to treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), particularly in patients with the challenging TP53 mutation. SL-325: Targeting the TL1A/DR3 PathwayIn an ambitious endeavor to address critical challenges in cancer and autoimmune disorders, Shattuck Labs has introduced a novel therapeutic agent: SL-325. This first-in-class Death Receptor 3 (DR3) antagonist targets the TL1A/DR3 signaling pathway. DR3, a member of the tumor necrosis factor receptor superfamily, is gaining attention for its role in modulating immune responses and contributing to inflammatory diseases and cancer pathophysiology.





Financial Statements
Shattuck Labs Inc's II. Quarter Investments $ 213 Millions STTK's Balance sheet
Shattuck Labs Inc's II. Quarter Income $ -15 Millions Quarterly STTK's Income Statement
STTK's Income by Division See STTK's Income by Division


STTK Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 84 82 146 180 274
Y / Y Investment Growth 2.24 % -43.84 % -18.91 % -34.18 % -17.51 %
Net Income in Millions -49 -75 -87 -102 -45
Y / Y Net Income Growth - - - - -
Annual Return On Investment -58.12 % -91.82 % -59.69 % -56.52 % -16.41 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
STTK's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for STTK's Competitors
Subscribers only: Roi for Shattuck Labs Inc's Suppliers
Subscribers only: Return On Investment for STTK's Customers

Other Ratios
STTK's Roa STTK's Inventory Turnover Ratio STTK's Growth Rates STTK's Dividend Statistics
STTK's Profitability Ratios STTK's Asset Turnover Ratio STTK's Dividend Growth
STTK's Roe STTK's Valuation Ratios STTK's Financial Strength Ratios STTK's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:38:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.